Akeso Biopharma, Inc. Sustainability Profile
Akeso Biopharma, Inc., a leading biopharmaceutical company headquartered in China, is at the forefront of innovative drug development. Founded in 2012, Akeso has rapidly established itself within the biotechnology industry, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in major operational regions across Asia and beyond, Akeso is renowned for its unique portfolio of core products, including innovative therapies for oncology and autoimmune diseases. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. Akeso's commitment to advancing healthcare through cutting-edge biopharmaceutical solutions underscores its reputation as a key player in the global biopharma landscape.
DitchCarbon Score
How does Akeso Biopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso Biopharma, Inc.'s score of 20 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akeso Biopharma, Inc.'s reported carbon emissions
Akeso Biopharma, Inc., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As a result, Akeso Biopharma's climate commitments remain unclear, and there are no inherited emissions data from a parent or related organization. The lack of emissions reporting and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy.
How Carbon Intensive is Akeso Biopharma, Inc.'s Industry?
How Carbon Intensive is Akeso Biopharma, Inc.'s Location?
Akeso Biopharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Akeso Biopharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
